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ABSTRACT: Engineered metalloproteins constitute a flex-
ible new class of analyte-sensitive molecular imaging agents
detectable by magnetic resonance imaging (MRI), but their
contrast effects are generally weaker than synthetic agents.
To augment the proton relaxivity of agents derived from the
heme domain of cytochrome P450 BM3 (BM3h), we
formed manganese(III)-containing proteins that have high-
er electron spin than their native ferric iron counterparts.
Metal substitution was achieved by coexpressing BM3h
variants with the bacterial heme transporter ChuA in
Escherichia coli and supplementing the growth medium with
Mn3þ-protoporphyrin IX. Manganic BM3h variants exhib-
ited up to 2.6-fold higher T1 relaxivities relative to native
BM3h at 4.7 T. Application of ChuA-mediated porphyrin
substitution to a collection of thermostable chimeric P450
domains resulted in a stable, high-relaxivity BM3h derivative
displaying a 63% relaxivity change upon binding of arachi-
donic acid, a natural ligand for the P450 enzyme and an
important component of biological signaling pathways. This
work demonstrates that protein-based MRI sensors with
robust ligand sensitivity may be created with ease by
including metal substitution among the toolkit of methods
available to the protein engineer.
To be useful in the laboratory or clinic, responsive MRIcontrast agents for molecular imaging must display large
1H NMR relaxivity changes at field strengths above 1 T.1,2 This
requirement presents a unique challenge for metalloprotein-based
contrast agents, which are limited by the natural magnetic and
solvent interaction parameters of protein-coordinated transition
metals3,4 or biomineralized deposits.5 A class of engineered ligand-
responsive contrast agents recently generated by us through directed
evolution of the heme domain of Bacillus megaterium cytochrome
P450 BM3 (BM3h)6 exemplifies this problem. Although BM3h-
based neurotransmitter sensors were shown to detect dopamine
release in living rat brains, the initial experiments were relatively
insensitive because of the low longitudinal (T1) relaxivity of these
proteins (r1≈ 1 mM-1 s-1 at 22 C and 4.7 T). BM3h derivatives
with improved relaxivity could offer better analyte sensitivity and
reduced potential for ligand buffering in vivo while continuing to
provide the advantages of a readily engineered protein framework for
tuning analyte binding properties.
Electron spin (S) is a critical factor governing theproton relaxivity
of metal ion complexes.7 BM3h variants contain a porphyrin-bound
ferric ion, which is thought to exist primarily in a low-spin (S = 1/2)
state. We therefore sought to increase the relaxivity of BM3h by
replacing the native heme with a protoporphyrin IX (PPIX)
complex containing a higher-spin (S = 2) Mn3þ ion.
Classical strategies for generating porphyrin-substituted heme
proteins are based on often cumbersome refolding protocols and are
generally impractical on the moderate- to high-throughput scale
demanded by protein engineering applications. More recent ap-
proaches require the use of specialized bacterial strains and can
involve restrictive growth conditions.8-10We found that porphyrin-
substituted BM3h variants could be expressed in high yield under
conventional culture conditions in a typical Escherichia coli BL21
strain by coinducing expression of the gene of interest with theE. coli
O157:H7 outer-membrane heme transporter ChuA.11-13 Cells
cotransformed with both BM3h- and ChuA-encoding plasmids
were grown in supplemented M9 minimal medium and induced
in the presence ofMn-PPIX (Figure 1A). Purifiedmanganic protein
yields of 20-30 mg/L of batch culture were easily obtained.
Mn3þ-substituted and native iron-containing proteins showed
identical mobilities in nondenaturing gel electrophoresis (Figure 1A
inset) and identical circular dichroism spectra (Figure 1B inset),
suggesting that the manganic and native ferric species are similarly
folded. Purified manganic BM3h (Mn-BM3h) exhibited a broad
Soret band with λmax = 386 nm, consistent with thiolate ligation of
themanganic ion14 and distinct fromboth ferric BM3h and freeMn-
PPIX (Figure S1 in the Supporting Information). Despite functional
heme biosynthesis machinery in expression cells, inductively
coupled plasma atomic emission spectroscopy confirmed that
>95% of the purified metalloprotein contained manganese. To
demonstrate the generality of the ChuA-based BM3h porphyrin
substitution technique for diverse potential applications, diamag-
netic Co3þ- and Zn2þ-containing PPIX species were also in-
serted in separate trials. Each gave rise to a species with a distinct
UV-vis absorbance spectrum (Figure 1B and Table S1 in the
Supporting Information).
Mn-BM3h exhibited a T1 longitudinal relaxivity of 2.6 ( 0.1
mM-1 s-1 at 23 C and 4.7 T, a 2-fold improvement over the
native ferric BM3h r1 of 1.3 ( 0.1 mM-1 s-1 (Figure 2A). The
relaxivity of Mn-BM3h peaked at lower field, and the greatest
absolute r1 difference between the manganic and ferric proteins
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was observed at 1.0 T. The Mn-BM3h relaxivities were also
comparable to r1 values recorded at similar field strengths for
other Mn-PPIX-substituted refolded proteins.15 Despite the
structural perturbation expected upon metal substitution,16
Mn-BM3h was slightly more stable than native BM3h. The
variants have thermal denaturation midpoint temperature
(T50) values of 54.6 and 51.9 C, respectively, as measured using
10 min incubation periods (Figure S2).17
To test the potential of Mn-BM3h to act as a ligand-dependent
responsive contrast agent, we examined its relaxivity change in the
presence of arachidonic acid (AA), a natural ligand shown to decrease
r1 by 66% upon binding to native BM3h.
6 While optical titration
(Figure S3) indicated that AA could bind to Mn-BM3h with a
dissociation constant (Kd) of 0.7( 0.5 μM, we found that the r1 of
wild-type Mn-BM3h changed by only 1.1% upon AA binding.
Proteins with improved basal relaxivity, stability, and ligand
responsiveness were observed from among a further set of Mn3þ-
substituted BM3h variants. The collection included a recently
reported variant engineered for dopamine sensing by MRI6 and
five thermostable chimeric P450 domains identified previously from
a library of artificially recombined BM3h homologues17 (Table S2).
Diverse combinations of r1 and T50 were observed among the
manganic variants (Figure 2B), indicating that both parameters can
be tuned by mutagenesis of the Mn-BM3h platform.
The Mn3þ-containing proteins with the highest relaxivities
and stabilities comparable to or better than wild-type Mn-BM3h
were titrated with AA to determine the correspondingKd values and
relaxivity changes upon binding. A variant called Mn-C1634
displayed the best combination of properties, with a relaxivity of
3.3 ( 0.2 mM-1 s-1, a T50 value of 56.0 ( 0.1 C, and an AA
dissociation constant of 2.5( 0.7μM.AAbinding resulted in a 63(
2.5% decrease in r1 and could be visualized by optical absorbance
changes or MRI (Figure 2C,D). Mn-C1634 also exhibited modest
T2 relaxivity (r2) averaging 7.4 ( 0.3 mM-1 s-1 over the AA
concentration range (Figure S4). Several potential competitors with
structural similarity to AA showed substantially less binding to
Mn-C1634 (Figure S5). These optical andMRI results indicate that
Mn-C1634 could be useful for imaging-based detection of AA in
tissue culture or living organisms, where AA is a key component of
inflammatory signaling and reaches concentrations as high as
100 μM in some contexts.18
The AA-dependent relaxivity change from 3.3 to 1.2 mM-1 s-1
in Mn-C1634 is greater by a factor of 2.4 than the Δr1 values
exhibited by first-generation ferric BM3h-based MRI sensors and
also comparable to high-field relaxivity changes reported in the
literature for synthetic Gd3þ-based responsive contrast agents.1
Through a combination of ChuA-mediated metal substitution and
traditional protein engineering techniques applied to BM3h, it could
be possible to access further gains in relaxivity aswell as alterations of
ligand specificity and other properties. The present work demon-
strates more generally that metal substitution techniques can be an
important component of efforts to engineer effective protein-based
sensors for molecular MRI.
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Figure 2. Longitudinal relaxivity and ligand responsiveness of Mn3þ-
substituted BM3h proteins. (A) Nuclear magnetic relaxation dispersion
profile ofwild-type (WT)Mn-BM3h (b) vs native ferric BM3h (O). Points
at 200 MHz were measured in a 4.7 T MRI scanner, and the remaining
points were obtained using a variable-field relaxometer. (B) Diverse
combinations of molar T1 relaxivity (r1) at 4.7 T and half-maximal
10 min denaturation temperature (T50) were observed among manganic
BM3h variants formed from WT BM3h, the dopamine sensor B7, and
thermostable chimeric BM3hhomologues (C1607,C1611,C1625, C1634,
and C1644). (C) Normalized optical absorbance changes of 5 μM
Mn-C1634 in PBS as a function of arachidonic acid (AA) concentration.
Error bars denote standard errors of the mean (n = 4). Data points were
computed from difference spectra (inset; higher AA concentrations corre-
spond to darker lines) by subtracting absorbance changes observed at λ =
380 and 430 nm (arrowheads). (D) Representative longitudinal molar
relaxivities (r1) observed at 4.7 T during an AA titration into 54 μM
Mn-C1634 in PBS. The inset shows corresponding spin-echo image data
with TR/TE = 1221/10 ms. Lines in C and D were obtained by fitting the
data to a two-component binding model.
Figure 1. Formation and characterization of purified metalloporphyrin-
substituted cytochrome P450 BM3h proteins. (A) Schematic showing
recombinant expression of metal-substituted BM3h species in E. coli
coexpressing BM3h (black) with the ChuA porphryin transporter
(green), supplemented with protoporphyrin IX (PPIX) complexes.
The gel fragment in the inset at the lower-right indicates equivalent
mobilities of purified ferric and manganic BM3h in nondenaturing 7.5%
polyacrylamide gel electrophoresis; the colored bands arise from natural
pigmentation of the proteins. (B) Absorbance spectra of purified wild-
type BM3h derivatives following coexpression with ChuA and purifica-
tion from cultures supplemented with 30 μg/mL Mn(III), Fe(III),
Co(III), or Zn(II) PPIX complexes. Inset: circular dichroism spectra
indicating the similarity of the secondary structures of ferric
and manganic BM3h in 10 mM potassium phosphate (pH 7.4) and
100 mM (NH4)2SO4.
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